Literature DB >> 23560922

Carbohydrate-based Clostridium difficile vaccines.

Mario A Monteiro1, Zuchao Ma, Lisa Bertolo, Yuening Jiao, Luis Arroyo, Douglas Hodgins, Michael Mallozzi, Gayatri Vedantam, Martin Sagermann, John Sundsmo, Herbert Chow.   

Abstract

Clostridium difficile is responsible for thousands of deaths each year and a vaccine would be welcomed, especially one that would disrupt bacterial maintenance, colonization and persistence in carriers and convalescent patients. Structural explorations at the University of Guelph (ON, Canada) discovered that C. difficile may express three phosphorylated polysaccharides, named PSI, PSII and PSIII; this review captures our recent efforts to create vaccines based on these glycans, especially PSII, the common antigen that has precipitated immediate attention. The authors describe the design and immunogenicity of vaccines composed of raw polysaccharides and conjugates thereof. So far, it has been observed that anti-PSII antibodies can be raised in farm animals, mice and hamster models; humans and horses carry anti-PSII IgA and IgG antibodies from natural exposure to C. difficile, respectively; phosphate is an indispensable immunogenic epitope and vaccine-induced PSII antibodies recognize PSII on C. difficile outer surface.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560922     DOI: 10.1586/erv.13.9

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  18 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 3.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 4.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

5.  Adaptive immune constraints on C. difficile vaccination.

Authors:  Mark L Lang; Binu Shrestha
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

6.  Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.

Authors:  Andrew D Cox; Frank St Michael; Annie Aubry; Chantelle M Cairns; Philippa C R Strong; Alexander C Hayes; Susan M Logan
Journal:  Glycoconj J       Date:  2013-08-23       Impact factor: 2.916

7.  α-Galactosylceramide-Reactive NKT Cells Increase IgG1 Class Switch against a Clostridioides difficile Polysaccharide Antigen and Enhance Immunity against a Live Pathogen Challenge.

Authors:  Gillian A Lang; Binu Shrestha; Souwelimatou Amadou Amani; Tyler M Shadid; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2021-08-23       Impact factor: 3.441

8.  Overview of Clostridium difficile infection: implications for China.

Authors:  Xinhua Chen; J Thomas Lamont
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-11-04

Review 9.  Clostridium difficile infection in the twenty-first century.

Authors:  Chandrabali Ghose
Journal:  Emerg Microbes Infect       Date:  2013-09-18       Impact factor: 7.163

10.  Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.

Authors:  Maria R Romano; Rosanna Leuzzi; Emilia Cappelletti; Marta Tontini; Alberto Nilo; Daniela Proietti; Francesco Berti; Paolo Costantino; Roberto Adamo; Maria Scarselli
Journal:  Toxins (Basel)       Date:  2014-04-22       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.